Development of in situ poloxamer-chitosan hydrogels for vaginal drug delivery of benzydamine hydrochloride: Textural, mucoadhesive and in vitro release properties

Creative Commons License


MARMARA PHARMACEUTICAL JOURNAL, vol.21, no.4, pp.762-770, 2017 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 4
  • Publication Date: 2017
  • Doi Number: 10.12991/mpj.2017.3
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.762-770
  • Keywords: Mucoadhesion, poloxamer, chitosan, hydrogel, benzydamine hydrochloride, vaginal drug delivery, POLY(METHYLVINYLETHER-CO-MALEIC ANHYDRIDE), GELS, SYSTEMS, POLYMERS, POLY(VINYLPYRROLIDONE), METRONIDAZOLE, FORMULATIONS
  • Gazi University Affiliated: Yes


The use of in situ hydrogel systems for vaginal drug delivery is an important strategy in the treatment of vaginitis. The aim of this study was to develop in situ vaginal hyrogels for benzydamine hydrochloride (BNZ) which were composed of poloxamer and chitosan. The reason for development of these hydrogels was to obtain a vaginal delivery system with improved mechanical and mucoadhesive properties that could provide prolonged retention time for the treatment of vaginits. The hydrogels were also designed for once a day dosage of the drug and to obtain a controlled release of the BNZ. For this purpose BNZ containing hydrogel formulations using thermosensitive polymer (Poloxamer 407) and mucoadhesive polymer (Chitosan H, Chitosan M and Chitosan L) were developed. The hydrogels are composed of polymers which have promising potential for vaginal delivery systems. These formulations were evaluated by rheology, texture, mucoadhesive profiles and drug diffusion with a Franz diffusion cell. It was observed that the diffusion of BNZ from the in situ poloxamer-chitosan hydrogel was more sustained and controlled than with the poloxamer gel. The hydrogel formulations diffused about 65.3 +/- 5.1, 80.6 +/- 3.8, 88.1 +/- 7.3 and 100.4 +/- 4.8% of BNZ at 6h. The formulation containing Poloxamer 407 and Chitosan H has the best controlled release profile and mucoadhesive properties, results which indicate that it could suitable for use once a day on the vaginal route. Moreover, the hydrogels higher mucoadhesion exhibited by this formulation prolongs the drug residence time compared with the poloxamer gel and may increase the BNZ efficacy. These BNZ mucoadhesive vaginal hydrogel formulations may be a promising alternative to conventional dosage forms for vaginal topical therapy.